3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
84
Carcinoma, Non-Small-Cell Lung
56
Triple Negative Breast Neoplasms
35
Breast Neoplasms
34
Neoplasms
28
Neoplasm Metastasis
28
Colorectal Neoplasms
17
Lung Neoplasms
13
Carcinoma, Pancreatic Ductal
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Adenocarcinoma
9
Stomach Neoplasms
8
Melanoma
8
Carcinoma
8
Ovarian Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms by Site
6
Fallopian Tube Neoplasms
6
Small Cell Lung Carcinoma
5
Carcinoma, Squamous Cell
5
Peritoneal Neoplasms
4
Head and Neck Neoplasms
4
Digestive System Neoplasms
4
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Sarcoma
3
Rectal Neoplasms
3
Pancreatic Diseases
3
Neoplasms by Histologic Type
3
Interventions
pembrolizumab
15
Pemetrexed
15
Cisplatin
12
Nivolumab
9
Carboplatin
8
Ipilimumab
7
tazemetostat
3
fludarabine
3
anetumab ravtansine
3
Cyclophosphamide
3
spartalizumab
2
budigalimab
2
belinostat
2
atezolizumab
2
amatuximab
2
Vinorelbine
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
venetoclax
1
vandetanib
1
trametinib
1
tocilizumab
1
tislelizumab
1
sotorasib
1
ruxolitinib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled